WO 2005/042009 PCT/US2004/034514

SEQUENCE LISTING

```
<110> Biogen Idec MA Inc.
Kalled, Susan
      Rao, Sambasiva
<120> Therapeutic regimens for BAFF antagonists
<130> 08201.0042-00304
<150> 60/512,880
<151> 2003-10-20
<160> 6
<170> PatentIn version 3.1
<210> 1
<211> 186
<212> PRT
<213> Human
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> None, or any amino acid
 <220>
 <221> MISC_FEATURE
 <222> (2)..(2)
<223> Methionine, none, or any amino acid
 <220>
 <221> MISC_FEATURE
<222> (21)..(21)
<223> valine (wild type), asparagine, or another amino acid
 <220>
 <221> MISC_FEATURE
<222> (28)..(28)
<223> lysine (wild type), proline, or another amino acid
  <220>
  <221> MISC_FEATURE
         (47) . . (47)
  <222>
  <223> None, any amino acid, or alanine
  <400> 1
  Xaa Xaa Arg Arg Gly Pro Arg Ser Leu Arg Gly Arg Asp Ala Pro Ala
  Pro Thr Pro Cys Xaa Pro Ala Glu Cys Phe Asp Xaa Leu Val Arg His
   Cys Val Ala Cys Gly Leu Leu Arg Thr Pro Arg Pro Lys Pro Xaa Ala
   Gly Ala Ser Ser Pro Ala Pro Arg Thr Ala Leu Gln Pro Gln Glu Ser
       50
```

PCT/US2004/034514 WO 2005/042009

Val Gly Ala Gly Ala Gly Glu Ala Ala Leu Pro Leu Pro Gly Leu Leu

Phe Gly Ala Pro Ala Leu Leu Gly Leu Ala Leu Val Leu Ala Leu Val

Leu Val Gly Leu Val Ser Trp Arg Arg Arg Gln Arg Arg Leu Arg Gly

Ala Ser Ser Ala Glu Ala Pro Asp Gly Asp Lys Asp Ala Pro Glu Pro 120

Leu Asp Lys Val Ile Ile Leu Ser Pro Gly Ile Ser Asp Ala Thr Ala 130

Pro Ala Trp Pro Pro Pro Gly Glu Asp Pro Gly Thr Thr Pro Pro Gly 155

His Ser Val Pro Val Pro Ala Thr Glu Leu Gly Ser Thr Glu Leu Val . 175 170

Thr Thr Lys Thr Ala Gly Pro Glu Gln Gln 180

<210> 2 <211> 321 <212> PRT

<213> Human

<220>

<221> MISC_FEATURE

<222> (41)...(41)

<223> Valine, aspragine, or another amino acid

<220>

<221> MISC_FEATURE

(48) . . (48)

<223> Lysine (wild type), proline, or another amino acid

<220>

<221> MISC_FEATURE

 $(67)^{-}$. (67)<222>

<223> none, any amino acid, or alanine

<400> 2

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Trp Val Pro

Gly Ser Thr Gly Asp Val Arg Arg Gly Pro Arg Ser Leu Arg Gly Arg

Asp Ala Pro Ala Pro Thr Pro Cys Xaa Pro Ala Glu Cys Phe Asp Xaa 40

Leu Val Arg His Cys Val Ala Cys Gly Leu Leu Arg Thr Pro Arg Pro 50 55

Lys Pro Xaa Ala Gly Ala Ser Ser Pro Ala Pro Arg Thr Ala Leu Gln 65 70 75 80

Pro Gln Glu Ser Val Gly Ala Gly Ala Gly Glu Ala Ala Val Asp Lys 85 90 95

Thr His Thr Ser Pro Pro Ser Pro Ala Pro Glu Leu Leu Gly Gly Pro 100 105 110

Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser 115 120 125

Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp 130 135

Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn 145 150 150

Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val 165 170 175

Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu 180 185 190

Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys 195 200 205

Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr 210 215 220

Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr 225 230 235 240

Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 245 250 255

Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu 260 265 270

Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 275 280 285

Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu 290 295 300

Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 305 310 315

PCT/US2004/034514 WO 2005/042009

Lys

<210> 3

<211> 175

<212> PRT murine <213>

<400> 3

Met Gly Ala Arg Arg Leu Arg Val Arg Ser Gln Arg Ser Arg Asp Ser

Ser Val Pro Thr Gln Cys Asn Gln Thr Glu Cys Phe Asp Pro Leu Val 20

Arg Asn Cys Val Ser Cys Glu Leu Phe His Thr Pro Asp Thr Gly His

Thr Ser Ser Leu Glu Pro Gly Thr Ala Leu Gln Pro Gln Glu Gly Ser 55

Ala Leu Arg Pro Asp Val Ala Leu Leu Val Gly Ala Pro Ala Leu Leu

Gly Leu Ile Leu Ala Leu Thr Leu Val Gly Leu Val Ser Leu Val Ser 85.

Trp Arg Trp Arg Gln Gln Leu Arg Thr Ala Ser Pro Asp Thr Ser Glu 100

Gly Val Gln Glu Ser Leu Glu Asn Val Phe Val Pro Ser Ser Glu 120

Thr Pro His Ala Ser Ala Pro Thr Trp Pro Pro Leu Lys Glu Asp Ala

Asp Ser Ala Leu Pro Arg His Ser Val Pro Val Pro Ala Thr Glu Leu 145

Gly Ser Thr Glu Leu Val Thr Thr Lys Thr Ala Gly Pro Glu Gln 165 .

<210> 4

<211> 316 <212> PRT <213> Murine

<400> 4

Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro

Gly Ser Thr Gly Asp Val Gly Ala Arg Arg Leu Arg Val Arg Ser Gln

WO 2005/042009 PCT/US2004/034514

25 30

Arg Ser Arg Asp Ser Ser Val Pro Thr Gln Cys Asn Gln Thr Glu Cys 35 40 45

Phe Asp Pro Leu Val Arg Asn Cys Val Ser Cys Glu Leu Phe His Thr 50 55

Pro Asp Thr Gly His Thr Ser Ser Leu Glu Pro Gly Thr Ala Leu Gln 65 70 75 80

Pro Gln Glu Gly Ser Ala Leu Val Asp Val Pro Arg Asp Cys Gly Cys 85 90 95

Lys Pro Cys Ile Cys Thr Val Pro Glu Val Ser Ser Val Phe Ile Phe 100 105 110

Pro Pro Lys Pro Lys Asp Val Leu Thr Ile Thr Leu Thr Pro Lys Val

Thr Cys Val Val Val Asp Ile Ser Lys Asp Asp Pro Glu Val Gln Phe 130 135

Ser Trp Phe Val Asp Asp Val Glu Val His Thr Ala Gln Thr Gln Pro 145 150 155 160

Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Ser Val Ser Glu Leu Pro 165 170 175

Ile Met His Gln Asp Trp Leu Asn Gly Lys Glu Phe Lys Cys Arg Val

Asn Ser Ala Ala Phe Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr 195 200 205

Lys Gly Arg Pro Lys Ala Pro Gln Val Tyr Thr Ile Pro Pro Pro Lys 210 215

Glu Gln Met Ala Lys Asp Lys Val Ser Leu Thr Cys Met Ile Thr Asp 225 230 230

Phe Phe Pro Glu Asp Ile Thr Val Glu Trp Gln Trp Asn Gly Gln Pro 245 250 250

Ala Glu Asn Tyr Lys Asn Thr Gln Pro Ile Met Asp Thr Asp Gly Ser 260 265

Tyr Phe Val Tyr Ser Lys Leu Asn Val Gln Lys Ser Asn Trp Glu Ala 275 280 285

Gly Asn Thr Phe Thr Cys Ser Val Leu His Glu Gly Leu His Asn His

WO 2005/042009 PCT/US2004/034514

290 295 300

His Thr Glu Lys Ser Leu Ser His Ser Pro Gly Lys 315

<210> 5
<211> 11
<212> PRT
<213> Artificial

<220>
<223> Peptide
<400> 5

Cys His Trp Asp Leu Leu Arg His Trp Val Cys 1

<210> 6
<211> 7
<212> PRT
<213> human
<400> 6

Ser Ser Pro Ala Pro Arg Thr 1 5